| 交易日 | 持股总数(股) | 持股变动(股) | 变动幅度 | | --- | --- | --- | --- | | 2026-01-23 | 515.05万 | 3.79万 | 0.74% | | 2026-01-22 | 511.26万 | -3.67万 | -0.71% | | 2026-01-21 | 514.92万 | -4.17万 | -0.80% | | 2026-01-20 | 519.09万 | 19.80万 | 3.97% | | 2026-01-19 | 499.29万 | -12.06万 | -2.36% | 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 证券之星消息，1月23日南向资金增持3.79万股讯飞医疗科技（02506.HK）。近5个交易日中，获南向资 金增持的有2天，累计净增持3.69万股。近20个交易日中，获南向资金增持的有8天，累计净增持111.23 万股。截至目前，南向资金持有讯飞医疗科技（02506.HK）515.05万股，占公司已发行普通股的 6.65%。 讯飞医疗科技股份有限公 ...

本报讯（西海新闻记者 莫青）1月16日，记者从全省医疗保障工作会议上获悉，今年医保部门持续优化 医疗保障服务，解决群众在医保领域办事的堵点难点问题。 在提升医保数据支撑能力方面，将着力推进"智慧医保"建设，优化信息平台功能与业务流程。通过持续 推广医保电子凭证、移动支付等数字化应用，扩大"刷脸"结算覆盖面，不断丰富便民应用场景。同时， 深化信息平台应用，优化网办业务流程，强化大数据赋能，进一步优化职工医保个人账户跨省共济使用 功能，推动更多医保公共服务实现"掌上办""网上办""视频办"。 在提升医保经办服务能力方面，将严格落实医保政务服务事项清单制度，规范服务流程和时限，深入推 进标准化窗口和示范点建设，巩固优化重点事项办理成效。大力推动跨部门关联业务"免材料办"、跨区 域业务"一窗通办"以及待遇兑现"即申即享"。 与此同时，将针对性开展干部能力提升工程，加强任职岗前培训和履职能力培训，持续组织政策学习、 技能比武和业务练兵，培养更多专业化医保人才。畅通社情民意反馈渠道，用好来信来访、网民留言等 途径，广泛听取意见，不断解决医保领域突出问题，使服务更契合群众需求。 提升医保及时结算能力方面，有序推进与定点医药 ...

Core Viewpoint - The company Shanda Diwei is undergoing significant changes, including a change in its controlling shareholder to Shandong High-speed Group and a proposed name change to Diwei Intelligent Technology Co., Ltd. This transition aims to enhance its business scope and leverage resources from its new parent company [3][4]. Group 1: Shareholder and Control Changes - In November 2025, Shanda Diwei's controlling shareholder will change from Shandong Shanda Capital Operation Co., Ltd. to Shandong High-speed Group, with the actual controller shifting from Shandong University to the Shandong Provincial State-owned Assets Supervision and Administration Commission [3]. - The company plans to change its name to Diwei Intelligent Technology Co., Ltd. and its stock abbreviation to Diwei Intelligent [3]. Group 2: Business Scope and Financial Performance - Shanda Diwei intends to expand its business scope to include information system integration services, blockchain technology-related software and services, data processing and storage support services, and internet data services [3]. - For the first three quarters of 2025, Shanda Diwei reported revenue of 326 million yuan, a year-on-year decrease of 0.89%, while net profit attributable to shareholders was 31.52 million yuan, an increase of 1.30% [3]. Group 3: Strategic Partnerships and Transactions - Following the transfer to Shandong High-speed Group, Shanda Diwei is expected to leverage the latter's resources to gain entry into transportation sector scenarios [4]. - The company anticipates selling products and services worth 70 million yuan to Shandong High-speed Group and its affiliates in 2026, which would account for 97.75% of similar business transactions [4]. Group 4: Board of Directors and Governance - The board of directors' election announcement indicates the nomination of several candidates with backgrounds in Shandong High-speed Group for the fifth board of directors [6]. - The company will hold its first extraordinary shareholders' meeting of 2026 on February 6, 2026, to review related proposals [8]. Group 5: Financial Management - Shanda Diwei plans to utilize up to 300 million yuan of temporarily idle funds for cash management over a 12-month period [7].

Group 1 - The core point of the article highlights that southbound funds have reduced their holdings in iFlytek Medical Technology (02506.HK) by 3,500 shares on January 8, with a total net reduction of 193,900 shares over the last five trading days [1] - Over the past 20 trading days, there have been 11 days of net reductions in southbound fund holdings, totaling 215,500 shares [1] - As of now, southbound funds hold 3,728,700 shares of iFlytek Medical Technology, which represents 4.82% of the company's total issued ordinary shares [1] Group 2 - iFlytek Medical Technology Co., Ltd. primarily provides AI-enabled medical solutions in China [1] - The company's business lines include grassroots medical services, hospital services, patient services, and regional management platform solutions [1] - The grassroots medical services line consists of intelligent medical assistants and chronic disease management, while the hospital services line includes smart hospital solutions and diagnostic assistance [1]

Core Viewpoint - Recent trading activity indicates a reduction in holdings by southbound funds in iFlytek Medical Technology, suggesting potential shifts in investor sentiment towards the company [1] Group 1: Trading Activity - On December 22, southbound funds reduced their holdings by 40,900 shares of iFlytek Medical Technology (02506.HK) [1] - Over the past five trading days, there have been four days of net reductions, totaling 107,900 shares [1] - In the last 20 trading days, there were 14 days of net increases, with a total of 91,600 shares added [1] - Currently, southbound funds hold 3,978,600 shares of iFlytek Medical Technology, representing 5.14% of the company's issued ordinary shares [1] Group 2: Company Overview - iFlytek Medical Technology Co., Ltd. primarily provides AI-enabled medical solutions in China [1] - The company's business lines include grassroots medical services (intelligent medical assistants and chronic disease management), hospital services (smart hospital solutions and diagnostic assistants), and patient services (smart hospital patient services and post-diagnosis management) [1] - The company also offers regional management platform solutions, including smart health solutions and smart medical insurance [1] - iFlytek Medical Technology mainly operates in the domestic market [1]

Industry Overview - The Chinese medical artificial intelligence industry has significant growth potential, driven by policy support for rapid development [1] - The market size of China's medical AI is projected to grow from 2.7 billion RMB in 2019 to 8.8 billion RMB in 2023, with a compound annual growth rate (CAGR) of 33.8%. It is expected to reach 315.7 billion RMB by 2033, with a CAGR of 43.1% from 2023 to 2033 [1] Company Capabilities - The company has developed its own foundational large model, the "Xunfei Xinghuo Medical Large Model X1," which is the only medical deep reasoning model trained entirely on domestic computing power. In real-world testing, its general auxiliary diagnosis accuracy reached 94.0% [2] - As of July 2025, the X1 model's performance has been upgraded, achieving a general auxiliary diagnosis accuracy of 95.0%, with improvements in various metrics such as health consultation response rate at 91.5% [2] Product and Service Development - By the end of 2024, the company has provided products and services to over 70,000 grassroots medical institutions across more than 30 provinces and 670 districts, including over 40 of China's top 100 hospitals [3] - The company's revenue from grassroots medical services grew by 52.3% in the first half of 2025, while the revenue from regional management platform solutions surged by 178.1% [3] - The company's To C business, which includes imaging cloud platforms and post-diagnosis management, saw a revenue growth of 10% in the first half of 2025 [3] Financial Projections - Revenue forecasts for 2025 to 2027 are estimated at 850 million RMB, 1.01 billion RMB, and 1.21 billion RMB, corresponding to price-to-sales (PS) ratios of 10.7x, 9x, and 7.5x respectively [4]

Investment Rating - The investment rating for the company is maintained as "Buy" with a target price of RMB 26.07 [1][4]. Core Insights - The company has shown signs of recovery in Q3, with a year-on-year revenue decline narrowing to 4.66%, compared to a 33.98% decline in H1 2025. This improvement is attributed to contributions from new businesses such as smart healthcare and electronic vouchers, while traditional business recovery is still dependent on local fiscal spending improvements [2][3]. - The company has increased its contract liabilities to RMB 76.07 million, reflecting a 43.89% quarter-on-quarter increase and a 67.37% year-on-year growth, indicating a sustained recovery in industry demand [2]. - The integration of AI with fiscal operations is expected to inject new momentum into traditional businesses, with new business revenue share anticipated to significantly increase [3]. Summary by Sections Financial Performance - For the first three quarters of 2025, the company reported revenue of RMB 364 million, a year-on-year decrease of 26.28%, and a net loss attributable to shareholders of RMB 64.24 million, a year-on-year increase of 1048.15% [1]. - In Q3 alone, revenue was RMB 124 million, with a net loss of RMB 15.80 million, showing a year-on-year improvement of 39.78% [1][2]. Business Outlook - The company is focusing on new business areas such as smart healthcare and electronic vouchers, which are expected to drive future growth. The smart healthcare wallet project has already served over 1.5 million insured individuals [3]. - The company is also enhancing its operational efficiency and cash flow management, with a year-on-year increase of 23.34% in operating cash flow for the first three quarters [2]. Profit Forecast and Valuation - The profit forecasts for 2025-2027 have been revised downwards significantly, with net profits projected at RMB 42.58 million for 2025, RMB 141.54 million for 2026, and RMB 230.33 million for 2027 [4][11]. - The target price adjustment is primarily due to changes in profit forecasts and comparable company valuations, with a target PE of 65 times for 2026 [4].

Core Viewpoint - The control change plan for Shanda Diwei (688579) has been finalized, with the controlling shareholder shifting from Shanda Capital to Shandong High-speed Group, and the actual controller changing from Shandong University to the State-owned Assets Supervision and Administration Commission of Shandong Province [1][5]. Control Change - Shanda Capital plans to transfer 24.59% of its shares in Shanda Diwei to Shandong High-speed Group without compensation, retaining 4.99% of the shares post-transfer [5]. - The control change process began on April 10, 2023, in response to national policies regarding the reform of enterprises affiliated with universities [5]. - Shanda Diwei's main business includes smart human resources, smart medical insurance, and intelligent electricity usage, with revenue primarily from government departments and institutions [5]. Financial Performance - In the first half of the year, Shanda Diwei achieved revenue of 209 million, a year-on-year increase of 0.46%, and a net profit attributable to shareholders of 19.77 million, a decrease of 5.18% compared to the previous year [5]. - Since the announcement of the control change plan, Shanda Diwei's stock price has increased by 26%, with a current market capitalization of 4.6 billion [5]. Industry Reform - The reform of enterprises affiliated with universities has been ongoing since 2018, with several universities, including Tsinghua University and Fudan University, actively pursuing asset divestiture [6]. - Shandong University is further advancing this reform, with another company, Ouma Software, also planning to transfer 25.82% of its shares to a state-owned investment holding company [6]. Talent and Innovation - Shanda Diwei benefits from a strong talent pool, including 8 professors and 6 doctoral supervisors, as well as several innovation platforms and collaborations with top universities [6]. - The company has established multiple research centers and platforms for technology transfer and collaboration, enhancing its business capabilities [6]. Operational Stability - The company has stated that the share transfer will not affect its normal production and operations, which are currently stable [7].

Core Viewpoint - The control change plan for Shanda Diwei (688579) has been finalized, with the controlling shareholder shifting from Shanda Capital to Shandong Expressway Group, and the actual controller changing from Shandong University to the State-owned Assets Supervision and Administration Commission of Shandong Province [2][6]. Group 1: Control Change Details - Shanda Capital plans to transfer 24.59% of its shares in Shanda Diwei to Shandong Expressway Group without compensation, retaining 4.99% of the shares post-transfer [6]. - The control change planning began on April 10, 2023, in response to national policies on the reform of enterprises affiliated with universities [6]. - The stock price of Shanda Diwei has increased by 26% since the announcement of the control change plan, with a current market capitalization of 4.6 billion [6]. Group 2: Business Performance - In the first half of the year, Shanda Diwei achieved revenue of 209 million, a year-on-year increase of 0.46%, and a net profit attributable to shareholders of 19.77 million, a decrease of 5.18% compared to the same period last year [6]. - The company primarily serves government departments, medical institutions, and social enterprises, focusing on smart human resources, smart medical insurance, and intelligent electricity usage [6]. Group 3: Industry Context - The reform of university-affiliated enterprises has been ongoing since 2018, with several universities, including Tsinghua University and Fudan University, actively divesting assets [7]. - Shanda Diwei benefits from a strong talent pool, including 8 professors and 6 doctoral supervisors, and has established multiple innovation platforms in collaboration with institutions like Nanyang Technological University [7]. - The company emphasizes the transformation and empowerment of cutting-edge technologies into its business through collaborative research projects [7]. Group 4: Operational Stability - Shanda Diwei has stated that the share transfer will not affect its normal production and operations, which are currently stable [8].

Core Viewpoint - Southbound funds reduced their holdings in iFlytek Medical Technology (02506.HK) by 5,550 shares on October 16, 2025, indicating a slight decrease in investor confidence in the short term [1]. Group 1: Southbound Fund Activity - In the last five trading days, southbound funds increased their holdings on three days, with a total net increase of 85,400 shares [1]. - Over the past 20 trading days, there were 16 days of net increases, totaling 253,400 shares [1]. - As of now, southbound funds hold 3,710,600 shares of iFlytek Medical Technology, accounting for 4.79% of the company's total issued ordinary shares [1]. Group 2: Company Overview - iFlytek Medical Technology Co., Ltd. primarily provides AI-enabled medical solutions in China [2]. - The company's business lines include grassroots medical services (intelligent medical assistants and chronic disease management), hospital services (smart hospital solutions and diagnostic assistants), and patient services (smart hospital patient services and post-discharge management) [2]. - The regional management platform solutions include smart health solutions and smart medical insurance [2].